Evidence map›Paper›PMID 39981090›Full record

ArticleFrontiers in medicine2025

Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies.

Jinqing Wu, Jianglong Hong, Hao Ding, Qiao Mei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinqing WuDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jianglong HongDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hao DingDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Qiao MeiDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives: An increasing number of patients with antithrombotic therapies are undergoing endoscopic retrograde cholangiopancreatography (ERCP). Interruption of antithrombotic therapies may be associated with a higher risk of symptomatic thromboembolic (TE) events. We aimed to investigate the risk of symptomatic TE events among patients undergoing ERCP. Methods: A retrospective cohort study on patients at risk for symptomatic TE events who had undergone ERCP from January 2016 to October 2023 was conducted. A total of 2,482 patients who had undergone ERCP were included in this study. We compared the risk of symptomatic TE events within 30 days after ERCP between the group treated with antithrombotic agent and the group not treated with antithrombotic agent using multivariate regression analysis adjusted for covariates. Results: A total of 15 patients (0.60%, 15/2,482) developed symptomatic TE events within 30 days after ERCP. The symptomatic TE event rate in subjects on any antithrombotic drug was 1.46% with an odds ratio (OR) of 5.267 ( Conclusion: Interruption of antithrombotic drugs is associated with higher post-ERCP symptomatic TE events, particularly in high-risk conditions.

Indexed as

antithrombotic therapiesbleedingendoscopic retrograde cholangiopancreatographyhigh-risk conditionssymptomatic thromboembolic events

Identifiers

PMID39981090
PMCPMC11839602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.